FUTURE OF HEALTHCARE

SpinaFX Medical to Exhibit at Society of Interventional Radiology Annual Scientific Meeting

Spinafx medical inc | June 13, 2022

SpinaFX Medical

Minimally invasive image-guided therapy company, SpinaFX Medical Inc. announced it will exhibit at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting in Boston, MA,��June 11-16, at booth 414. Dr. Alexis Kelekis, medical advisor to SpinaFX, will present the results of a research study on which he was the lead author, recently published in The Spine Journal, on the effectiveness of intradiscal oxygen-ozone treatment compared to microdiscectomy for contained lumbar disc herniation with radiculopathy. This study has been recognized by SIR as one of the 2022 Abstracts of the Year.

"We are excited to meet with some of the world's leading interventional radiologists to discuss innovations in minimally invasive, image-guided care and share our recent progress and momentum at SpinaFX. We look forward to Dr. Kelekis' presentation and celebrate the study's findings, which have the potential to benefit both patients and providers by addressing a significant gap in the continuum of care for the millions suffering from back pain."

Jeff Cambra, SpinaFX CEO

"I am thrilled that Dr. Kelekis will share the findings of our skilled research team at SIR's Annual Scientific Meeting," said Dr. Kieran Murphy, SpinaFX Chief Medical Officer and co-author of the recognized study. "The technology used in this randomized control trial holds great promise for patients struggling with contained herniated lumbar disc pain and it is an honor to have this research recognized by such a prestigious and well-respected organization."

Dr. Alexis Kelekis will present the results of his study on Wednesday, June 15, at 10:40 a.m. during Closing Plenary.

As an exhibitor during the meeting on June 11-16, SpinaFX will offer attendees the opportunity to discuss the study results and their implications with Drs. Kelekis and Murphy, learn more about SpinaFX and its goal to help develop minimally invasive, image-guided treatment options, and provide input on developing technology with the potential to redefine the treatment of contained herniated discs. Visit SIR's website to learn more about the Annual Scientific Meeting.

About SpinaFX

Headquartered in Ontario, Canada, SpinaFX is a treatment solution and technology company bringing innovative, minimally invasive image-guided treatments to patients with back pain due to contained herniated discs.

Spotlight

Every employer needs to provide their employee health
plan members with access to providers when the member
is away from home or when they need access to a
specialist that isn’t available in their primary network.

Spotlight

Every employer needs to provide their employee health
plan members with access to providers when the member
is away from home or when they need access to a
specialist that isn’t available in their primary network.

Related News

HEALTHTECH SECURITY, DIGITAL HEALTHCARE

CHA Hollywood Presbyterian Medical Center Launches Fetal Surgery Program

CHA Hollywood Presbyterian Medical Center | January 23, 2023

Hollywood Presbyterian Medical Center (CHA HPMC), a member of CHA Health Systems, recently announced a new partnership with Los Angeles Fetal Surgery to provide life-saving and revolutionary fetal surgery to pregnant women and their unborn babies with birth defects. It will be the only fetal surgery center in the U.S. Los Angeles Fetal Surgery, a joint program between USC and Children's Hospital Los Angeles, offers minimally invasive fetal treatments to reduce or cure adverse outcomes due to fatal conditions, which would otherwise result in the baby's death or irreversible organ damage. Dr. Ramen Chmait, an international expert in minimally invasive fetal surgery, will direct the program. He has produced over 200 manuscripts and book chapters in fetal medicine and surgery over the past 20 years. "The goal of the Los Angeles Fetal Surgery Program at CHA Hollywood Presbyterian is to treat unborn babies with innovative treatments while providing families with emotional support," said Ramen Chmait, MD, who also serves as an OB-GYN with Keck Medicine of USC. (Source- Business Wire) "Our collaborative structure ensures our patients have access to a wide variety of services and specialists. This affiliation with CHA HPMC only strengthens our commitment to successful outcomes,” he further added. (Source- Business Wire) According to the CDC, 1 in 33 U.S. newborns is born with a serious condition. The program will treat Spina Bifida, Vasa Previa, and Twin-Twin Transfusion Syndrome. CHA HPMC, Los Angeles' second-largest maternity center, provides excellent prenatal and postpartum care. Fetal surgery will help CHA HPMC serve its community and improve results for expectant families. About CHA Hollywood Presbyterian Medical Center CHA Hollywood Presbyterian Medical Center (CHA HPMC) is a full-service hospital, providing acute care to the multicultural population of Hollywood and its neighboring regions since 1924. CHA Bio Group is known worldwide for its high-quality health care and advances in reproductive medicine. CHA HPMC has 469 acute care beds and 89 skilled nursing beds. The hospital employs about 550 doctors from 69 disciplines and 75 nationalities. It treats its various multicultural patients with kindness and compassion. CHA Health Systems, a dynamic global healthcare corporation with 86 hospitals and clinics, 30 research and 14 education institutes, along with 31 bio/pharmaceutical/healthcare enterprises, provides a wide range of services in seven countries.

Read More

DIGITAL HEALTHCARE, MEDICAL DEVICES

Sofwave Medical Announces FDA Clearance of SUPERB™ Technology For Cellulite

SofWave Medical, Ltd. | December 20, 2022

Sofwave Medical Ltd an emerging leader in energy-based non-invasive, aesthetic medical devices announced the U.S. Food and Drug Administration’s clearance of Sofwave’s SUPERB™ technology to be used for the short-term improvement in the appearance of cellulite. Dr. Shimon Eckhouse, Chairman & Co-Founder commented on the occasion, “We are pleased to receive FDA clearance to use the Company's proprietary SUPERB™ technology to improve the appearance of cellulite in the short term. Non-invasive treatment of cellulite is one of the most desired body treatments in medical aesthetics because of the high prevalence of cellulite in women of all ages and the lack of effective and safe solutions with no patient down-time. Sofwave has shown once again that its investment in the development of the SUPERB™ technology to treat highly prevalent aesthetic indications bears significant fruit and will support the continued rapid growth of the Company. Our disruptive SUPERB™ technology was designed to be efficient and easy to use, and the Company invests and plans to continue investing in bringing innovative solutions to the growing aesthetic technology market generating great ROI to our physician customers.” In the clinical trials submitted to the FDA as part of the 510(k) application in support of the cellulite FDA clearance, the Company conducted a multi-site clinical study that evaluated the safety and effectiveness of the device for the non-invasive dermatological aesthetic improvement in cellulite appearance. A total of 68 women were treated at 4 sites in the United States. Eligible patients received 2 treatments using SUPERB™ technology on one side (right or left) of the lateral / posterior upper thigh or buttocks. Serial clinical photographs were collected under standardized conditions before treatment and at the 3-month follow-up visits. Photographs were assessed by blinded independent reviewers to identify pre-treatment images when compared to post treatment images and to grade the pre-treatment and post-treatment images using the Cellulite Severity Scale (CSS). Improvement was also evaluated using the Global Aesthetic Improvement Scale (GAIS) and Laxity Scale (LS). Safety assessments included evaluation of adverse events via physician examination during and after the treatment. Post-study, the blinded reviewers correctly identified the post treatment images for 89% of the subjects. No serious or unanticipated adverse event was reported during the study. “The FDA's clearance of SUPERB™ for use in cellulite could not have come at a timelier moment. Our dedicated U.S. direct sales force is positioned to expand our growing presence and market share of the aesthetic medical device market in the U.S. In addition, our recent regulatory clearance in Brazil further extends our global footprint, letting us immediately launch sales in this important and sizeable market. Furthermore, our partnership in China with HTDK, one of Asia's strongest healthcare solutions providers, covers our expansion in that territory. Our focused commitment across these major markets, will go a long way towards further accelerating global sales and brand-recognition of our devices in the upcoming new year.” Lou Scafuri, Sofwave's CEO In 2021, the FDA cleared additional indications for SUPERB™ technology, for lifting the eyebrow and lifting lax submental tissue (beneath the chin) and neck tissue; which can also affect the appearance of lax tissue in the submental neck regions. In addition, the Sofwave SUPERB™ technology is also cleared by the U.S. FDA for a non-invasive dermatological aesthetic treatment to improve facial lines and wrinkles. About SUPERB™ Sofwave’s state-of-the-art SUPERB™ Technology addresses the growing demand for non-invasive treatments that deliver noticeable results in non-invasive treatment of highly desired aesthetic indications. The device’s cooled transducers are directly coupled to the epidermis, creating a unique 3D array of volumetric thermal zones that deliver parallel energy simultaneously, heating precisely at the right depth in the mid-dermis. A single Sofwave treatment reduces facial wrinkles in a fast 30 to 45 minute non-invasive treatment with no interruption to a patient’s daily routine or post-treatment discomfort. About Sofwave Medical Sofwave Medical Ltd. has implemented an innovative approach to wrinkle reduction lifting and cellulite using proprietary breakthrough technology. SUPERB™, Synchronous Ultrasound Parallel Beam technology is FDA-cleared to improve facial lines and wrinkles, lifting the eyebrow and lifting lax submental tissue (beneath the chin) and neck tissue and the short term improvement in the appearance of cellulite providing physicians with smart yet simple, effective, and safe aesthetic solutions for their patients.

Read More

FUTURE OF HEALTHCARE

Veradigm Digital Health Media Becomes the First EHR Marketing Solution to Join the Point of Care Marketing Association

Veradigm | November 23, 2022

Veradigm, a business unit of Allscripts announced The Point of Care Marketing Association a nonprofit organization to support the continued growth of the Point of Care channel through education and advocacy, has welcomed Veradigm to its membership. Veradigm Digital Health Media is the first EHR marketing solution to be accepted as a member of POCMA Stuart Green, Senior Vice President & General Manager, Veradigm has joined POCMA’s board of directors POCMA exists to advocate for the effective use of the point of care communication channel to advance patient healthcare outcomes. Members of the nonprofit point of care industry association work closely with brand, agency, and provider stakeholders to advocate for the channel and promote its positive impact to ensure its continued growth as a vital and innovative segment of healthcare marketing. “POCMA is excited to have Veradigm as a member and the first within the EHR landscape. Veradigm’s platform of reaching HCPs in their workflow makes them an excellent resource for the association and its members. We look forward to their insights and involvement as we grow the POC industry.” POCMA Executive Director, Nicole Divinagracia “At Veradigm, we share in POCMA’s goal of raising healthcare providers’ awareness through innovative point of care marketing channels,” said Stuart Green, Senior Vice President & General Manager, Veradigm. “With our membership, we look forward to contributing to the establishment of industry best practices and building connections with other point-of-care industry leaders and influencers.” About Allscripts Allscripts is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. Some healthcare technology companies deliver clinical data for biopharma and health plans, some help turn that data into insights, others serve healthcare providers directly by providing point-of-care clinical software and patient outreach platforms. Veradigm does it all. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully.

Read More